Switzerland: Pharma Deal Wuxi STA to Acquire Bristol Myers Squibb’s Manufacturing Unit in Switzerland

Editor: Ahlam Rais

Located in Couvet, Switzerland, Bristol Myers Squibb’s manufacturing facility will be Wuxi STA’s first plant in Europe. On completion of the deal, Wuxi STA is expected to acquire the Couvet site’s operations and assets.

Related Vendors

Bristol Myers Squibb and Wuxi STA anticipate completing the transaction by Q2 2021, subject to regulatory approvals and the satisfaction of other closing conditions.
Bristol Myers Squibb and Wuxi STA anticipate completing the transaction by Q2 2021, subject to regulatory approvals and the satisfaction of other closing conditions.
(Source: Bristol Myers Squibb)

USA – Bristol Myers Squibb and Wuxi STA – a subsidiary of Wuxi Apptec – have recently announced that Wuxi STA has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland. The Couvet site will be the first facility in Europe for Wuxi STA, a leading Contract Development and Manufacturing Organization. The acquisition will enhance Wuxi STA’s existing capabilities while growing capacity to support its partners’ life-saving work.

The companies anticipate completing the transaction by Q2 2021, subject to regulatory approvals and the satisfaction of other closing conditions. Upon closing, Wuxi STA will acquire the Couvet site’s operations and assets, which include the plant and equipment, as well as a workforce with technical capabilities and expertise.

China’s Pharmaceutical Equipment Market - Current Status, Trends and Recommendations for Action

As China is emerging as one of the world’s fastest-growing markets for the consumption of pharmaceuticals, it also offers huge opportunities for the global equipment industry.

This 40-page report aims to help you gain a better understanding of the current China's pharmaceutical market regarding a series of pharmaceutical industry related policies. Based on results of the survey among users in the pharmaceutical industry and the expert interviews, it will also provide you with a forecast for the industry and recommendations for your future operating and investment in China.

“The Couvet site is a world-class facility designed for quality, safety, and efficiency, and we believe Wuxi STA will be able to leverage the capacity and capabilities for its own operations as it continues to play a vital role for patients around the world,” said Lou Schmukler, Executive Vice President and President, Global Product Development and Supply, Bristol Myers Squibb. “This is an important step in the ongoing evolution of our manufacturing network to support our product portfolio. Switzerland remains an important strategic location for Bristol Myers Squibb, and we look forward to maintaining a strong presence in the Neuchâtel area.”

“We are pleased to add the Couvet manufacturing facility to our growing global manufacturing site network and look forward to working with the talented team who share our focus on excellence and a patient-centered approach,” said Dr. Minzhang Chen, CEO of Wuxi STA. “The acquisition will allow Wuxi STA to better serve European markets and support our global customers to deliver innovative medicines and treatments to patients around the world.”

The Couvet facility will continue to operate as part of Bristol Myers Squibb’s manufacturing network until the closing of the transaction.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:47113882)